{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T12:22:07Z","timestamp":1788524527114,"version":"build-2803163510"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100018693","name":"Horizon Europe","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.pharma.2026.08.003","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:41:01Z","timestamp":1787240461000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["\u00c9tudes de faisabilit\u00e9 pr\u00e9coce en Europe\u00a0: enjeux, perspectives et impacts attendus pour l\u2019\u00e9valuation clinique des dispositifs m\u00e9dicaux"],"prefix":"10.1016","author":[{"given":"Ornella","family":"Tangila Kayembe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tess","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"van der Loo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majella","family":"Geraghty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luisa","family":"Buzelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Banks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuditta","family":"Callea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Martelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharma.2026.08.003_bib0190","unstructured":"R\u00e8glement (UE) 2017\/745\u00a0du Parlement europ\u00e9en et du Conseil du 5\u00a0avril 2017\u00a0relatif aux dispositifs m\u00e9dicaux, modifiant la directive 2001\/83\/CE, le r\u00e8glement (CE) no\u00a0178\/2002\u00a0et le r\u00e8glement (CE) no\u00a01223\/2009\u00a0et abrogeant les directives du Conseil 90\/385\/CEE et 93\/42\/CEE (texte pr\u00e9sentant de l\u2019int\u00e9r\u00eat pour l\u2019EEE) [Internet]. [cited 2025\u00a0August 1]. Available from: https:\/\/eur-lex.europa.eu\/eli\/reg\/2017\/745\/oj\/fra."},{"key":"10.1016\/j.pharma.2026.08.003_bib0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1109\/JTEHM.2022.3194415","article-title":"The European medical device regulation\u00a0\u2013\u00a0what biomedical engineers need to know","volume":"10","author":"Melvin","year":"2022","journal-title":"IEEE J Transl Eng Health Med"},{"key":"10.1016\/j.pharma.2026.08.003_bib0200","unstructured":"European Committee for Standardization. ISO 14155:2020\u00a0Clinical investigation of medical devices for human subjects - Good clinical practice [Internet]. 2020. Available from: https:\/\/www.iso.org\/standard\/71690.html."},{"key":"10.1016\/j.pharma.2026.08.003_bib0205","unstructured":"FDA Center for Devices and Radiological Health. Investigational Device Exemptions (IDEs) for Early Feasibility Medical Device Clinical Studies, Including Certain First in Human (FIH) Studies [Internet]. 2013 [cited 2024\u00a0Jun 19]. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/investigational-device-exemptions-ides-early-feasibility-medical-device-clinical-studies-including."},{"key":"10.1016\/j.pharma.2026.08.003_bib0210","unstructured":"HEU-EFS_ DELIVERABLE 1.1\u00a0Characteristics, gaps, and best practices of pre-market programs [Internet]. 2024 [cited 2025\u00a0October 16]. Available from: https:\/\/ec.europa.eu\/research\/participants\/documents\/downloadPublic?documentIds=080166e5167ae766&appId=PPGMS."},{"key":"10.1016\/j.pharma.2026.08.003_bib0215","unstructured":"HEU-EFS_ DELIVERABLE 1.3\u00a0Characteristics and state of play of EFS [Internet]. 2024 [cited 2025\u00a0October 16]. Available from: https:\/\/ec.europa.eu\/research\/participants\/documents\/downloadPublic?documentIds=080166e5169113cc&appId=PPGMS."},{"issue":"1","key":"10.1016\/j.pharma.2026.08.003_bib0220","doi-asserted-by":"crossref","first-page":"e77982","DOI":"10.2196\/77982","article-title":"Stakeholder perspectives on early feasibility studies for digital health technologies in the European union: qualitative interview study","volume":"27","author":"Peseke","year":"2025","journal-title":"J Med Internet Res"},{"issue":"8","key":"10.1016\/j.pharma.2026.08.003_bib0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/17434440.2026.2693727","article-title":"Pre-market clinical investigation approval pathways and the role of Early Feasibility Studies for medical devices: a scoping review to guide EU policy","volume":"23","author":"Banks","year":"2026","journal-title":"Expert Rev Med Devices"},{"key":"10.1016\/j.pharma.2026.08.003_bib0230","unstructured":"HEU-EFS_ DELIVERABLE 2.1\u00a0EU regulatory framework and international standards 2024\u00a0disponible via https:\/\/ec.europa.eu\/research\/participants\/documents\/downloadPublic?documentIds=080166e5103c8d1d&appId=PPGMS."},{"issue":"3","key":"10.1016\/j.pharma.2026.08.003_bib0235","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00246-020-02296-0","article-title":"Regulatory science, and how device regulation will shape our future","volume":"41","author":"Ibrahim","year":"2020","journal-title":"Pediatr Cardiol"},{"key":"10.1016\/j.pharma.2026.08.003_bib0240","unstructured":"Consortium (MDIC) MDI. Blueprint for early feasibility study success: a report of the Early Feasibility Study working group of the Medical Device Innovation Consortium (MDIC) [Internet]. 2016. Available from: https:\/\/mdic.org\/resource\/mdic-efs-blueprint\/."},{"issue":"4","key":"10.1016\/j.pharma.2026.08.003_bib0245","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/17434440.2022.2075729","article-title":"Recommendations for the design and implementation of an early feasibility studies program for medical devices in the European Union","volume":"19","author":"Callea","year":"2022","journal-title":"Expert Rev Med Devices"},{"issue":"17","key":"10.1016\/j.pharma.2026.08.003_bib0250","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1016\/j.jacc.2016.07.769","article-title":"Overcoming the challenges of conducting early feasibility studies of medical devices in the United States","volume":"68","author":"Holmes","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharma.2026.08.003_bib0255","unstructured":"Harmonised approach to early feasibility studies for medical devices in the European Union (HEU-EFS) Project. HEU EFS [Internet]. [cited 2025\u00a0August 1]. Available from: https:\/\/heuefs.eu\/the-project\/."},{"key":"10.1016\/j.pharma.2026.08.003_bib0260","unstructured":"CORDIS | European Commission [Internet]. [cited 2025\u00a0August 1]. Harmonised approach to early feasibility studies for medical devices in the European union | HEU-EFS | Projekt | Fact Sheet | HORIZON. Available from: https:\/\/cordis.europa.eu\/project\/id\/101112185."},{"key":"10.1016\/j.pharma.2026.08.003_bib0265","series-title":"Etude de faisabilit\u00e9 pr\u00e9coce\u202f: un outil pertinent \u00e0 mettre en place au niveau europ\u00e9en","author":"Barbot","year":"2023"},{"key":"10.1016\/j.pharma.2026.08.003_bib0270","unstructured":"Medical Device Coordination Group. MDCG 2021-6\u00a0Rev. 1\u00a0Regulation (EU) 2017\/745\u00a0\u2013\u00a0Questions & Answers regarding clinical investigation [Internet]. 2023. Available from: https:\/\/health.ec.europa.eu\/system\/files\/2023-12\/mdcg_2021-6_en.pdf."},{"key":"10.1016\/j.pharma.2026.08.003_bib0275","unstructured":"HEU-EFS_ DELIVERABLE 3.1\u00a0Eligibility criteria for EFS [Internet]. 2025 [cited 2025\u00a0October 16]. Available from: https:\/\/ec.europa.eu\/research\/participants\/documents\/downloadPublic?documentIds=080166e51a53124e&appId=PPGMS."},{"issue":"6","key":"10.1016\/j.pharma.2026.08.003_bib0280","first-page":"1784","article-title":"Regulatory strategies for early device development and approval","volume":"99","author":"Holmes","year":"2022","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.pharma.2026.08.003_bib0285","series-title":"A decade of innovation in medical device testing","author":"Victoria","year":"2024"},{"issue":"6","key":"10.1016\/j.pharma.2026.08.003_bib0290","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.jcin.2016.02.004","article-title":"Clinical perspective\u00a0\u2013\u00a0early feasibility device medical studies in the United States: time for more than regulatory reform","volume":"9","author":"Holmes","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.pharma.2026.08.003_bib0295","unstructured":"HEU-EFS_ DELIVERABLE 2.2\u00a0Professional and organizational characteristics of competent authorities [Internet]. 2025 [cited 2025\u00a0October 16]. Available from: https:\/\/ec.europa.eu\/research\/participants\/documents\/downloadPublic?documentIds=080166e5193cb4d0&appId=PPGMS."},{"issue":"1","key":"10.1016\/j.pharma.2026.08.003_bib0300","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/17434440.2025.2594460","article-title":"Regulatory readiness for innovation: a mixed-methods study of national competent authority professional and organizational capacities in the context of pre-market clinical investigations and early feasibility studies","volume":"23","author":"Geraghty","year":"2026","journal-title":"Expert Rev Med Devices"},{"key":"10.1016\/j.pharma.2026.08.003_bib0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinthera.2026.06.003","article-title":"Early feasibility studies in Europe: a multisite qualitative study of operational challenges and site selection determinants at 6 university hospitals","author":"Valledor","year":"2026","journal-title":"Clin Ther"},{"key":"10.1016\/j.pharma.2026.08.003_bib0310","series-title":"Breakthrough medical devices: information session","year":"2026"},{"key":"10.1016\/j.pharma.2026.08.003_bib0315","series-title":"New pilot to support development of \u2018breakthrough\u2019 medical, devices","year":"2026"},{"key":"10.1016\/j.pharma.2026.08.003_bib0320","unstructured":"Medical Device Coordination Group. MDCG 2025-9\u00a0Guidance on Breakthrough Devices (BtX) under Regulations 2017\/745 & 2017\/746 [Internet]. Available from: https:\/\/health.ec.europa.eu\/document\/download\/edca94c7-62ab-4dd5-8539-2b347bd14809_en?filename=mdcg_2025-9.pdf."},{"issue":"1","key":"10.1016\/j.pharma.2026.08.003_bib0325","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3171\/2020.11.JNS203653","article-title":"US FDA best practices for initiating early feasibility studies for neurological devices in the United States","volume":"136","author":"Herrmann","year":"2022","journal-title":"J Neurosurg"},{"key":"10.1016\/j.pharma.2026.08.003_bib0330","unstructured":"ANSM [Internet]. [cited 2025\u00a0October 16]. Dispositifs m\u00e9dicaux\u00a0\u2013\u00a0demander une autorisation pour une inves. Available from: https:\/\/ansm.sante.fr\/vos-demarches\/industriel\/demander-une-autorisation-pour-un-essai-clinique-pour-des-dispositifs-medicaux-categorie-1."},{"key":"10.1016\/j.pharma.2026.08.003_bib0335","unstructured":"European Parliament. Regulation (EU) 2017\/745\u00a0of the European Parliament and of the Council of 5\u00a0April 2017\u00a0on medical devices, amending Directive 2001\/83\/EC, Regulation (EC) No 178\/2002\u00a0and Regulation (EC) No 1223\/2009\u00a0and repealing Council Directives 90\/385\/EEC and 93\/42\/EEC (text with EEA relevance.). OJ L [Internet]. 2017\u00a0April 5. Available from: http:\/\/data.europa.eu\/eli\/reg\/2017\/745\/oj\/eng."},{"issue":"2","key":"10.1016\/j.pharma.2026.08.003_bib0340","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1053\/j.tvir.2017.04.001","article-title":"Regulation and device development: tips for optimizing your experience with the food and drug administration","volume":"20","author":"Brooks","year":"2017","journal-title":"Tech Vasc Interv Radiol"},{"key":"10.1016\/j.pharma.2026.08.003_bib0345","unstructured":"European Medicines Agency. Pilot on the advice from the expert panels to manufacturers of high-risk medical devices\u00a0\u2013\u00a0interim report [Internet]. 2025. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/report\/pilot-advice-expert-panels-manufacturers-high-risk-medical-devices-interim-report-experience-pilot-february-2023-december-2024_en.pdf."},{"issue":"23","key":"10.1016\/j.pharma.2026.08.003_bib0350","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1016\/j.jacc.2020.10.019","article-title":"Early feasibility studies for cardiovascular devices in the United States: JACC state-of-the-art review","volume":"76","author":"Holmes","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharma.2026.08.003_bib0355","unstructured":"HEU-EFS_ DELIVERABLE 2.4\u00a0Research report summarizing the current EU regulatory framework for clinical evidence generation for MDs and DHTs and relations with the future EU EFS Program (Part 2\u00a0\u2013\u00a0Focus on DHTs) [Internet]. 2024 [cited 2025\u00a0October 16]. Available from: https:\/\/ec.europa.eu\/research\/participants\/documents\/downloadPublic?documentIds=080166e5191a2945&appId=PPGMS."},{"key":"10.1016\/j.pharma.2026.08.003_bib0360","unstructured":"Medical Device Coordination Group. MDCG 2024-5\u00a0guidance on content of the Investigator's Brochure for clinical investigations of medical devices [Internet]. 2024. Available from: https:\/\/health.ec.europa.eu\/document\/download\/ee7ee8eb-841a-4085-a8dc-af6d55ebf1bd_en?filename=mdcg_2024-5_en.pdf."},{"key":"10.1016\/j.pharma.2026.08.003_bib0365","unstructured":"R\u00e8glement (UE) 2021\/2282\u00a0du Parlement europ\u00e9en et du Conseil du 15\u00a0d\u00e9cembre 2021\u00a0concernant l\u2019\u00e9valuation des technologies de la sant\u00e9 et modifiant la directive 2011\/24\/UE (texte pr\u00e9sentant de l\u2019int\u00e9r\u00eat pour l\u2019EEE). OJ L [Internet]. 2021\u00a0December 15. Available from: http:\/\/data.europa.eu\/eli\/reg\/2021\/2282\/oj\/fra."},{"key":"10.1016\/j.pharma.2026.08.003_bib0185","unstructured":"Regulation (EU) 2024\/1689\u00a0of the European Parliament and of the Council of 13\u00a0June 2024\u00a0laying down harmonised rules on artificial intelligence and amending Regulations (EC) No. 300\/2008, (EU) No 167\/2013, (EU) No. 168\/2013, (EU) 2018\/858, (EU) 2018\/1139\u00a0and (EU) 2019\/2144\u00a0and Directives 2014\/90\/EU, (EU) 2016\/797\u00a0and (EU) 2020\/1828 (Artificial Intelligence Act) (text with EEA relevance) [Internet]. 2024\u00a0June 13. Available from: http:\/\/data.europa.eu\/eli\/reg\/2024\/1689\/oj\/eng."}],"container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450926001367?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450926001367?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T12:10:31Z","timestamp":1788523831000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003450926001367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":37,"alternative-id":["S0003450926001367"],"URL":"https:\/\/doi.org\/10.1016\/j.pharma.2026.08.003","relation":{},"ISSN":["0003-4509"],"issn-type":[{"value":"0003-4509","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u00c9tudes de faisabilit\u00e9 pr\u00e9coce en Europe\u00a0: enjeux, perspectives et impacts attendus pour l\u2019\u00e9valuation clinique des dispositifs m\u00e9dicaux","name":"articletitle","label":"Article Title"},{"value":"Annales Pharmaceutiques Fran\u00e7aises","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharma.2026.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Acad\u00e9mie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}